CD155

Istari Oncology Announces Publication of Phase 1 Data Showing PVSRIPO Immunotherapy Leads to Objective Responses in Patients with Treatment-Refractory Melanoma

Retrieved on: 
Wednesday, April 21, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Medicine, Clinical medicine, Cancer treatments, Clusters of differentiation, Immune system, Antineoplastic drugs, Cancer, Melanoma, Targeted therapy, CD155, Programmed cell death protein 1, Cancer immunotherapy, PVSRIPO, Istari Oncology, PVSRIPO, ISTARI ONCOLOGY

The results of this study suggest that PVSRIPO holds promise for patients with advanced melanoma refractory to both PD-1 inhibitors and BRAF-targeted therapy.1\nTwelve patients received 1, 2, or 3 intratumoral injections of PVSRIPO at 21-day intervals.

Key Points: 
  • The results of this study suggest that PVSRIPO holds promise for patients with advanced melanoma refractory to both PD-1 inhibitors and BRAF-targeted therapy.1\nTwelve patients received 1, 2, or 3 intratumoral injections of PVSRIPO at 21-day intervals.
  • Responses were observed in both injected and noninjected tumors, suggestive of an abscopal response.
  • PVSRIPO has a distinct target (the poliovirus receptor, CD155), which is expressed on virtually all solid tumors and antigen-presenting cells.
  • A phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma.

Genentech to Present First Clinical Data on Novel Anti-TIGIT Cancer Immunotherapy Tiragolumab at ASCO

Retrieved on: 
Wednesday, May 13, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Branches of biology, Medical specialties, Organ systems, TIGIT, Atezolizumab, Immune system, CD155, Poliovirus, PD-L1, Transitional epithelium, Transitional cell carcinoma, Urinary bladder

By binding to TIGIT, tiragolumab blocks its interaction with a protein called poliovirus receptor (PVR, or CD155) that can suppress the bodys immune response.

Key Points: 
  • By binding to TIGIT, tiragolumab blocks its interaction with a protein called poliovirus receptor (PVR, or CD155) that can suppress the bodys immune response.
  • Blockade of TIGIT and PD-L1 may synergistically enable the re-activation of T cells and enhance NK cell antitumor activity.
  • Tecentriq is a prescription medicine used to treat adults with:
    A type of bladder and urinary tract cancer called urothelial carcinoma.
  • The approval of Tecentriq in these patients is based on a study that measured response rate and duration of response.